New antibiotic could treat drug-resistant gonorrhea: Study
The drug, called gepotidacin, works by preventing bacteria from replicating in the body and was approved by the Food and Drug Administration in March to treat uncomplicated urinary tract infections in women and in girls 12 years and older.
If approved to treat gonorrhea, it will be the newest antibiotic to treat the sexually transmitted infection since the 1990s.
The drug is manufactured by the pharmaceutical company GSK and is sold under the name Blujepa.
After reaching a historic low in 2009, cases of gonorrhea in the United States steadily increased until 2021 and have slowly declined since then, according to the Centers for Disease Control and Prevention (CDC).
Still, gonorrhea is the second most common sexually transmitted infection in the country with, 601,319 reported cases in 2023, according to the agency.
Gonorrhea, and other sexually transmitted infections, are becoming more difficult to treat as they become increasingly more resistant to existing antibiotics.
The CDC currently recommends providers treat gonorrhea with a 500 mg injection of the antibiotic ceftriaxone. The agency updated its treatment guidelines in 2023, directing providers to administer a higher dose of the drug to combat antibiotic resistance.
Justin Gill, an urgent care nurse practitioner and president of the Washington State Nurses Association, told The Hill that he frequently treats gonorrhea and has encountered cases of the infection that are resistant to ceftriaxone.
'There are only a handful of antibiotics that are available as backup options,' he said. 'The development of new antibiotics has been slow, but federal investment in new and emerging antibiotic options is necessary before resistant strains of gonorrhea expand further.'
If left untreated, gonorrhea can cause serious health complications that can lead to infertility in both men and women, and it can increase the odds of contracting and passing HIV, according to the CDC.
The trial of more than 620 people showed gepotidacin was about 92 percent effective in treating the infection among those who took the drug twice a day. Meanwhile, a regimen of combination ceftriaxone and azithromycin was about 91 percent effective.
Stuart Ray, an infectious disease professor at Johns Hopkins University School of Medicine who did not take part in the study, said that any progress in safely and effectively treating gonorrhea is 'exciting.' He added that the fact that the drug can be administered in pill form makes it 'attractive.'
'In general, it's very exciting to see a late-stage trial for a new antimicrobial for a thorny problem like gonorrhea,' he said. 'I think it's very exciting to see data and progression of an agent this far down the path.'
Ray said that of the more than 600 trial participants, less than 10 percent were women.
'We have to be careful about making conclusions about subgroups that may have been somewhat underrepresented.'
Copyright 2025 Nexstar Media, Inc. All rights reserved. This material may not be published, broadcast, rewritten, or redistributed.
Try Our AI Features
Explore what Daily8 AI can do for you:
Comments
No comments yet...
Related Articles
The Hill
an hour ago
- The Hill
Pediatric group bucks RFK Jr. on kids' COVID shots
The American Academy of Pediatrics (AAP) recommended Tuesday that children between 6 months and 23 months old receive the vaccine to protect them against serious illness caused by the virus. Kids under the age of 2 are especially vulnerable to severe COVID-19, the group said, and should be prioritized for vaccination unless they have an allergy to the jab or its ingredients. In May, Kennedy announced that the Centers for Disease Control and Prevention (CDC) would no longer recommend routine COVID-19 shots for healthy children due to a lack of clinical data justifying the need for annual vaccinations against the virus. But the CDC did not follow Kennedy's guidance to the letter, instead recommending that parents take part in a 'shared decision making' process with health care providers to determine if their child needs the shot. The AAP and HHS have been at odds for months, and tensions reached a head when Kennedy dismissed all the members of the CDC's Advisory Committee on Immunization Practices (ACIP) and replaced them with his own handpicked representatives, including some outright vaccine skeptics. Since it was founded in 1930, the AAP has published evidence-based vaccine guidance to support pediatricians. But it has not traditionally differed substantially from federal recommendations. The move to publish COVID recommendations that break from HHS reflects a new effort by medical societies and expert advocacy groups to bypass Kennedy and what they say are his efforts to upend the nation's vaccine system. With vaccine skeptics in charge of U.S. health care, these groups say they want to give Americans — especially parents — as much information as possible to protect children from disease. At the same time AAP's recommendations were released, a group of epidemiologists and infectious diseases experts called the Vaccine Integrity Project held essentially their own version of an ACIP meeting to review evidence on the safety and efficacy for flu, COVID and RSV shots. Members of the initiative said ACIP usually reviews guidelines for respiratory virus vaccines during the summer, but has not appeared to have done it this year. In its absence, the initiative was stepping in. The panel concluded there was no change in safety signals or sudden drop in efficacy on any of the vaccines reviewed. 'There is no scientific evidence to support the changes HHS made to COVID recommendations for pregnant women or for children most at risk for high-risk transmission of severe disease,' said Michael Osterholm, director of the Center for Infectious Disease Research and Policy at the University of Minnesota, who is leading the initiative.
Boston Globe
an hour ago
- Boston Globe
Defying RFK Jr., pediatric group urges COVID shots for young kids
Get Starting Point A guide through the most important stories of the morning, delivered Monday through Friday. Enter Email Sign Up 'The majority of what we've seen from the secretary has been a pretty clearly orchestrated strategy to sow distrust in vaccines,' said Sean O'Leary, a physician who heads the AAP's infectious-diseases committee. 'We make our recommendations based on what's in the best interest of the health of children.' Advertisement Andrew Nixon, a spokesman for Kennedy, said AAP, which has received funding from vaccine manufacturers, should 'strengthen conflict-of-interest safeguards and keep its publications free from financial influence.' 'By bypassing the CDC's advisory process and freelancing its own recommendations, while smearing those who demand accountability, the AAP is putting commercial interests ahead of public health and politics above America's children,' Nixon said in a statement. Advertisement The country is in the midst of a summer uptick in coronavirus cases, and the future of vaccine access is uncertain. The Centers for Disease Control and Prevention did not go as far as Kennedy directed and did not remove coronavirus vaccines from the childhood immunization schedule. Instead, the public health agency softened its recommendation for all children to receive an annual coronavirus shot. It now recommends parents consult a doctor to decide whether to vaccinate their children. The AAP took a similar approach for older children. Its new guide says healthy children ages 2 to 18 can receive a coronavirus vaccine if their parents or guardians want them to have that protection. Few parents do. The CDC estimates that 13 percent of all eligible children are up-to-date on coronavirus vaccines, as well as 4.5 percent of children between the ages of 6 months and 23 months. By issuing a broader coronavirus vaccine recommendation for young children, the AAP is trying to boost uptake and keep the shots free. Between October 2022 and April 2024, a little more than half of children between the ages of 6 months and 23 months admitted to intensive care for COVID had no underlying conditions, a CDC study found. Still, the vast majority of children infected by coronavirus will have mild symptoms, and few will become hospitalized. Health officials say it has become difficult to measure the effectiveness of coronavirus vaccines in young children because the vaccination rates are so low. Limited data show the 2024-2025 coronavirus vaccines provided extra protection against severe illness in children and adults compared with people who did not receive a vaccine, according to CDC data presented in June. Advertisement But pediatric infectious-disease specialists have argued that regularly vaccinating children makes sense as a public health strategy because evidence has shown each year that protection in children is similar to that seen in adults. Federal officials have yet to approve or recommend an updated coronavirus vaccine, which usually debuts in late summer. The Food and Drug Administration has signaled it would not license upcoming coronavirus vaccines for otherwise healthy children. Kennedy recently fired all members of the CDC's Advisory Committee on Immunization Practices, a group of experts who decide who should receive FDA-approved or authorized vaccines. Four of the seven members Kennedy appointed as replacements have been publicly critical of the broad use of coronavirus vaccines. For the past three decades, the AAP and the CDC have been mostly aligned in their vaccine recommendations — until now. The AAP's schedule 'differs from recent recommendations of the Advisory Committee on Immunization Practices of the CDC, which was overhauled this year and replaced with individuals who have a history of spreading vaccine misinformation,' the organization said in a statement. Under federal law, insurers must cover the cost of ACIP-recommended vaccinations. The AAP and other professional organizations have been holding discussions with insurance companies to continue covering the shots based on guidance from professional associations rather than the federal government. O'Leary said insurers 'are signaling that they are committed to covering our recommendations.' AHIP, the major insurance lobby, has said its members are committed to continue paying for respiratory virus vaccines this season. The new ACIP panel did not make any coronavirus recommendations when it met for the first time in late June. It may not even convene a special meeting to discuss the coronavirus vaccines until mid-September, according to industry employees and CDC officials who spoke on the condition of anonymity to share sensitive information. That timing has become more uncertain after the Aug. 8 shooting at the CDC that severely damaged several buildings and traumatized CDC staff. The ACIP is scheduled to hold a meeting in October. Advertisement The AAP's full vaccine guidance, published Tuesday in the organization's clinical guidebook for infectious-diseases prevention and treatment, represents formal recommendations for immunizations for infants, children, and adolescents against 18 diseases. Its recommendations for flu and respiratory syncytial virus, or RSV, are essentially the same as what federal health officials, including Kennedy, have recommended.
American Military News
an hour ago
- American Military News
Gov't agency exposed for allowing drugs from dangerous foreign factories into the US: Report
A new report claims that the U.S. Food and Drug Administration secretly allowed substandard foreign factories with dangerous manufacturing issues to ship hundreds of medications to the United States despite being officially banned by the agency. In June, ProPublica reported that a group of individuals inside the Food and Drug Administration exempted drugs shipped to the U.S. from foreign factories despite the agency banning imports from certain factories due to contamination and other issues. The outlet noted that pills and other medications exempted from the bans were distributed to Americans and claimed that the agency did not regularly test the drugs for quality issues or track the medications to determine whether the medications were causing harm. According to ProPublica, Janet Woodcock, a former Food and Drug Administration employee, told the outlet, 'We felt we didn't have to make it a public thing.' READ MORE: Experimental vaccine may prevent recurrence of cancer In a new report, ProPublica claimed that the Food and Drug Administration did not adequately monitor various reports filed by medical providers and other individuals who warned that some drugs had a bad odor, residue, or abnormal taste. The outlet claimed that the government agency also did not adequately monitor reports of patients experiencing abnormal health issues potentially related to certain medications. According to ProPublica, the Food and Drug Administration largely withheld the information regarding the medication import ban exemptions from the American public and has not shared a list of medications that the U.S. government allowed into the country from foreign factories banned by the agency. However, ProPublica released a list of the drugs and ingredients that the outlet determined were exempted from import bans since 2013. The list also reveals the manufacturing companies responsible for the production of the medications. ProPublica reported that the news outlet found that the Food and Drug Administration exempted over 150 medications and ingredients from import bans. While the majority of the exempted products came from India, ProPublica reported that a Chinese factory and a Hungarian factory were also exempted by the federal agency.
